Dorsey Wright & Associates Invests $1.24 Million in argenex SE $ARGX

Dorsey Wright & Associates purchased a new stake in shares of argenex SE (NASDAQ:ARGX) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,479 shares of the company’s stock, valued at approximately $1,244,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. M&T Bank Corp raised its holdings in argenex by 20,977.7% during the 4th quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock worth $654,772,000 after purchasing an additional 774,916 shares during the last quarter. Sands Capital Management LLC boosted its stake in shares of argenex by 2,046.6% in the 4th quarter. Sands Capital Management LLC now owns 356,870 shares of the company’s stock valued at $300,110,000 after purchasing an additional 340,245 shares during the last quarter. Invesco Ltd. boosted its stake in shares of argenex by 390.4% in the 4th quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock valued at $350,178,000 after purchasing an additional 331,489 shares during the last quarter. Wellington Management Group LLP grew its position in shares of argenex by 80.1% during the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after buying an additional 324,653 shares during the period. Finally, Two Sigma Investments LP grew its position in shares of argenex by 570.3% during the 3rd quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after buying an additional 250,278 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ARGX has been the topic of several analyst reports. Wedbush restated an “outperform” rating and issued a $1,000.00 price objective on shares of argenex in a report on Thursday, June 11th. Wells Fargo & Company lifted their target price on shares of argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a report on Monday, June 1st. Deutsche Bank Aktiengesellschaft upgraded shares of argenex from a “hold” rating to a “buy” rating in a research report on Tuesday, March 10th. Guggenheim increased their price target on argenex from $1,120.00 to $1,135.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Finally, Robert W. Baird raised their price target on argenex from $858.00 to $867.00 and gave the stock a “neutral” rating in a research report on Friday, February 27th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,019.50.

argenex Stock Down 1.6%

Shares of ARGX stock opened at $877.72 on Friday. argenex SE has a 12-month low of $510.05 and a 12-month high of $934.62. The firm has a market capitalization of $54.59 billion, a price-to-earnings ratio of 39.08, a price-to-earnings-growth ratio of 1.36 and a beta of 0.47. The firm has a fifty day moving average of $822.61 and a 200-day moving average of $810.57.

argenex (NASDAQ:ARGX) last released its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. The business had revenue of $1.31 billion during the quarter. argenex had a net margin of 31.31% and a return on equity of 44.37%. Research analysts expect that argenex SE will post 26.19 earnings per share for the current year.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.